aTyr Pharma Announces Research Collaboration with Montefiore Einstein
Key Highlights
- ➤aTyr announces research collaboration with Montefiore Einstein on ATYR2810 in pediatric osteosarcoma
- ➤ATYR2810 targets NRP2, implicated in aggressive cancer progression, drug resistance and metastasis
- ➤ATYR2810 completed GLP toxicology testing in non-human primates and cGMP manufacturing
- ➤ATYR2810 showed anti-tumor effects across multiple preclinical cancer models
Expert Statements
Bang H. Hoang, Arnold and Madaleine Penner Professor and Co-Director of Orthopaedic Oncology, Montefiore Einstein
“Aggressive solid tumors like osteosarcoma present a profound therapeutic challenge due to an immunosuppressive microenvironment. By selectively blocking the NRP2 signaling pathway, ATYR2810 is designed to disrupt myeloid-driven immune suppression and turn the tumor’s own defense mechanism against itself.”
Bang H. Hoang, Arnold and Madaleine Penner Professor and Co-Director of Orthopaedic Oncology, Montefiore Einstein
“This innovative strategy potentially offers a highly differentiated approach capable of altering the local tumor niche to mitigate both primary tumor progression and critical metastasis.”
Sanjay S. Shukla, President and Chief Executive Officer of aTyr Pharma
“We are pleased to collaborate with Montefiore Einstein and Dr. Hoang, a leader in pediatric bone cancer, on this important research regarding the role of NRP2 in pediatric osteosarcoma.”
Sanjay S. Shukla, President and Chief Executive Officer of aTyr Pharma
“While our focus has been on our tRNA synthetase-derived therapies, we have continued to contribute to the understanding of NRP2 in cancer through our research collaborations, and this collaboration presents an opportunity to investigate its role in another aggressive cancer where NRP2 is implicated.”
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a research collaboration with Albert Einstein College of Medicine to further the development and testing of ATYR2810, the Company’s monoclonal antibody that targets the neuropilin-2 (NRP2) receptor. The collaboration will be led by Bang H. Hoang, M.D., Arnold and Madaleine Penner Professor and Co-Director of Orthopaedic Oncology in the Department of Orthopaedic Surgery at Montefiore Einstein. Dr. Hoang’s research focuses on the pathophysiology and molecular mechanisms of bone and soft tissue cancer, including evaluating the role of NRP2 in pediatric bone cancers such as osteosarcoma.
“Aggressive solid tumors like osteosarcoma present a profound therapeutic challenge due to an immunosuppressive microenvironment. By selectively blocking the NRP2 signaling pathway, ATYR2810 is designed to disrupt myeloid-driven immune suppression and turn the tumor’s own defense mechanism against itself,” said Dr. Hoang. “This innovative strategy potentially offers a highly differentiated approach capable of altering the local tumor niche to mitigate both primary tumor progression and critical metastasis.”
Get started
Create a free account to read the full story.